2026 is the inflection point where biotechnology stops being priced on promise and starts being priced on conversion. This isn’t a change in sentiment. It’s a change in operating constraints. Capital, regulators, and operators now press the same question: can you keep truth intact as a programme moves from concept to scale—through handoffs, pressure, and […]
Tag: Scale-up
Why 2026 Is the Year Systems Beat Stories
(A note on: biotech, techbio, food tech, and the new operating physics of “real companies”) Every cycle reaches a point where narrative stops clearing the bar. The change is not theatrical. It shows up as a shift in diligence questions—questions that are operational, specific, and hard to bluff. When the questions change, the valuation framework […]
Biotech in 2026: The Real Bottlenecks in Scale-Up, Manufacturing, Capital, and Regulation
Where Biotech Actually Fails: Scale Is Not an Extension of the Lab Biotech still tells itself that scale is a later problem. In biotech in 2026, that belief is no longer naive — it is actively dangerous. The lab works.The data looks good.The organism behaves.The molecule binds.The titer hits the slide. And somewhere between that […]
From Zero to One in Biotech: Transforming Ideas into Therapies & Partnerships
We bring clarity to the vision within your company. In business, as in science, the most mythologized leap is the one from zero to one. It is the first spark, the improbable moment where an idea becomes reality, where nothing gives way to something. In biotechnology, this leap carries particular weight: a first molecule expressed, […]